Sunho Biologics gets green light for downsized IPO
The loss-making developer of cancer immunotherapies raised just enough financing last year to cross the valuation threshold for a Hong Kong listing Key Takeaways: Sunho Biologics has no revenue or…
New Horizon Health launches probe into disputed sales figures
The provider of cancer-screening products issued a positive profit alert in January, but the full earnings report has yet to appear after auditors raised questions about the company’s revenues Key…
BenQ files for IPO as business looks stable, but with few growth spots
China’s biggest private for-profit hospital operator plans to use funds from its planned listing to expand and upgrade its facilities Key Takeaways: BenQ Hospital has filed to list in Hong…
InSilico seeks IPO boost to get AI drugs over the line
The drug developer has raised around $400 million in seven rounds of financing. But after burning through cash, the company needs fresh capital to sustain its work on AI-assisted drugs…
ProfoundBio discovers the joys of having a wealthy owner
The company has become the latest in a recent string of China-related innovative drug makers to be purchased by larger foreign buyers Key Takeaways: Cancer treatment maker ProfoundBio announced it…
Akeso marks profit milestone with swift rights issue
Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs Key Takeaways: Akeso swung to an…
PODCAST: Japanese Auto Cuts, and a Drugmaker’s Fall
By Doug Young & Rene Vanguestaine Nissan and Honda weigh major cuts of up to 30% in their China car production. What's driving the trend, and is it likely to…
Recent Articles
RELATED ARTICLES
-
Funding boost gets Sunho Biologics over the IPO filing line
-
Cash-strapped Viva Biotech sells stake and plans spinoff
1873.HK
-
WuXi Biologics hatches new baby with ADC drug unit IPO
2269.HK
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
-
New Horizon Health finds formula for profits ahead of schedule
6606.HK
- Payment app Lianlian seeks IPO relief from cash crunch
-
Akeso marks profit milestone with swift rights issue
9926.HK
